Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release

Hydrocodone Polistirex and Chlorpheniramine Polistirex · HYDROCODONE BITARTRATE 10 mg/5mL; CHLORPHENIRAMINE MALEATE 8 mg/5mL · Suspension, Extended Release · Oral · Cranbury Pharmaceuticals, LLC

NDC 27808-0086-01 · 1 BOTTLE, UNIT-DOSE in 1 CARTON / 115 mL in 1 BOTTLE, UNIT-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $0.4782 per mL over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

104 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed

$56.50

Reported to Texas DSHS · 2026 annual filing · Cranbury Pharmaceuticals, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$5,724

264 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for hydrocodone polistirex and chlorpheniramine polistirex (other) in the next 90 days

price up 30% YoY · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program · Opioid Analgesic REMS Shared System REMS

Regulatory

Application: ANDA091632
TE code: —
Approval date: Oct 1, 2010
Patents / exclusivity: None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

Class II · TerminatedJul 11, 2019
Tris Pharma Inc. — Superpotent Drug and Failed Stability Specifications: High out-of-specification results for the active ingredients, hydrocodone and chlorpheniramine, as well as high out-of-specification results for the preservatives.

Manufacturers of Hydrocodone Polistirex and Chlorpheniramine Polistirex (Suspension, Extended Release)

Labeler	Strength	First seen	Last seen
Bryant Ranch Prepack	HYDROCODONE BITARTRATE 10 mg/5mL; CHLORPHENIRAMINE MALEATE 8 mg/5mL	Aug 26, 2026	Sep 3, 2026
Cranbury Pharmaceuticals, LLC	HYDROCODONE BITARTRATE 10 mg/5mL; CHLORPHENIRAMINE MALEATE 8 mg/5mL	Aug 26, 2026	Sep 2, 2026
Bryant Ranch Prepack	HYDROCODONE BITARTRATE 8 mg/5mL; CHLORPHENIRAMINE MALEATE 10 mg/5mL	Jul 22, 2026	Aug 22, 2026
Cranbury Pharmaceuticals, LLC	HYDROCODONE BITARTRATE 8 mg/5mL; CHLORPHENIRAMINE MALEATE 10 mg/5mL	Jul 22, 2026	Aug 19, 2026
Bryant Ranch Prepack	CHLORPHENIRAMINE MALEATE 8 mg/5mL; HYDROCODONE BITARTRATE 10 mg/5mL	Jul 15, 2026	Jul 18, 2026
Cranbury Pharmaceuticals, LLC	CHLORPHENIRAMINE MALEATE 8 mg/5mL; HYDROCODONE BITARTRATE 10 mg/5mL	Jul 15, 2026	Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release — NDC 27808-0086-01," retrieved September 3, 2026, https://drugdashboards.com/drug/27808008601.

Free to cite with attribution — see how the data is put together.